S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Armata Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ARMP)

$2.06
+0.03 (+1.48%)
(As of 11/28/2023 ET)
Compare
Today's Range
$1.99
$2.12
50-Day Range
N/A
52-Week Range
$0.83
$5.26
Volume
1,722 shs
Average Volume
59,191 shs
Market Capitalization
$74.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Armata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
239.8% Upside
$7.00 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.71) to ($0.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars


ARMP stock logo

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

ARMP Stock Price History

ARMP Stock News Headlines

Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Lexeo Therapeutics Inc.
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
ARMP - Armata Pharmaceuticals, Inc.
See More Headlines
Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
11/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ARMP
CIK
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+230.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-36,920,000.00
Net Margins
-1,468.73%
Pretax Margin
-1,468.71%

Debt

Sales & Book Value

Annual Sales
$5.51 million
Book Value
$1.00 per share

Miscellaneous

Free Float
5,241,000
Market Cap
$76.64 million
Optionable
Not Optionable
Beta
0.99
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Mina Pastagia M.D. (Age 48)
    MS, Chief Medical Officer
    Comp: $537.6k
  • Dr. Deborah L. Birx M.D. (Age 66)
    CEO & Director
  • Dr. Wenyuan Shi Ph.D.
    Co-Founder & Founding Scientist
  • Mr. Richard Rychlik (Age 67)
    VP, Corporate Controller & Principal Financial Officer
  • Mr. Bryan Kadotani
    Vice President of Program Management & Operations
  • Dr. Pierre Kyme Ph.D.
    Vice President of Business & Corporate Development














ARMP Stock Analysis - Frequently Asked Questions

Should I buy or sell Armata Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares.
View ARMP analyst ratings
or view top-rated stocks.

What is Armata Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12 month price targets for Armata Pharmaceuticals' stock. Their ARMP share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 239.8% from the stock's current price.
View analysts price targets for ARMP
or view top-rated stocks among Wall Street analysts.

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 99,700 shares, a decline of 25.4% from the October 15th total of 133,700 shares. Based on an average daily volume of 38,800 shares, the short-interest ratio is currently 2.6 days. Currently, 0.9% of the shares of the company are sold short.
View Armata Pharmaceuticals' Short Interest
.

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The business earned $1.23 million during the quarter, compared to analyst estimates of $0.90 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 280.95% and a negative net margin of 1,468.73%.

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ARMP) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -